Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 SHY TherapeuticsPrivate | 1 asset: 1 Ph 1 | SHY-ONC6Phase 1 · Non-Small Cell Lung Cancer | 15 May 2027SHY-ONC6 · Phase 1 |
 SK Chemicals285130 · KOSPI | 1 asset: 1 Ph 3 | cilostazol/Ginkgo bilobaPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | None on record |
 SQ InnovationPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 STADA ArzneimittelPrivate | 1 asset: 1 Ph 1 | TrigelPhase 1 · Parkinson's DiseasePartial signal | None on record |
 STCube, Inc.052020 · KOSDAQ | 1 asset: 1 Ph 2 | NelmastobartPhase 2 · Non-Small Cell Lung Cancer | 31 Aug 2027Nelmastobart · Phase 2 |
 STERO Biotechs LtdPrivate | 1 asset: 1 approved | Approved assets only | 1 Aug 2027Cannabidiol (Epidiolex) · Approved |
 Sagimet Biosciences Inc.SGMT · Nasdaq | 1 asset: 1 Ph 3 | DenifanstatPhase 3 · MASH / NASHReliable signal | None on record |
 Sairopa B.V.Private | 1 asset: 1 Ph 1 | ADU-1805Phase 1 · Non-Small Cell Lung Cancer | May 2027ADU-1805 · Phase 1 |
 Salubris Biotherapeutics IncPrivate | 1 asset: 1 Ph 2 | JK08Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 SanionaSANION · Nasdaq Stockholm | 1 asset: 1 Ph 2 | TesofensinePhase 2 · ObesityReliable signal | None on record |
 Saol Therapeutics Inc.Private | 1 asset: 1 approved | Approved assets only | None on record |
 Sardocor (Medera Biopharma)Private | 1 asset: 1 Ph 2 | AAV1.SERCA2aPhase 1/2 · Heart Failure | Oct 2027AAV1.SERCA2a · Phase 1 |
 Sarfez PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record |
SatRxPrivate | 1 asset: 1 Ph 3 | GosogliptinPhase 3 · Type 2 DiabetesPartial signal | None on record |
| 1 asset: 1 approved | Approved assets only | None on record | |
 Savara Inc.SVRA · Nasdaq | 1 asset: 1 Ph 3 | molgramostimPhase 3 · Autoimmune Pulmonary Alveolar Proteinosis | Jun 2027molgramostim · Phase 3 |
 Scholar RockSRRK · Nasdaq | 1 asset: 1 Ph 3 | apitegromabPhase 3 · Spinal Muscular AtrophyPartial signal | 1 Nov 2026apitegromab · Phase 3 |
Scilex BioPrivate | 1 asset: 1 Ph 2 | KDS2010Phase 2 · Alzheimer's Disease | 31 Jan 2027KDS2010 · Phase 2 |
 Scilex PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record |
| 1 asset: 1 Ph 1 | SNH-118110Phase 1 · Non-Small Cell Lung Cancer | 26 Jun 2027SNH-118110 · Phase 1 | |
 Seanergy DermatologyPrivate | 1 asset: 1 Ph 1 | SNG100Phase 1 · Atopic DermatitisPartial signal | None on record |
 Seaport TherapeuticsSPTX · Nasdaq | 1 asset: 1 Ph 2 | GlyphAllo (allopregnanolone prodrug)Phase 2 · Major Depressive Disorder | Mar 2027GlyphAllo (allopregnanolone prodrug) · Phase 2 |
 Second Life TherapeuticsPrivate | 1 asset: 1 Ph 2 | SL-28Phase 1/2 · Non-Small Cell Lung Cancer | 1 Jan 2027SL-28 · Phase 1/2 |
 Secretome TherapeuticsPrivate | 1 asset: 1 Ph 1 | STM01Phase 1 · Heart Failure | None on record |
 Seismic TherapeuticPrivate | 1 asset: 1 Ph 1 | S-4321Phase 1 · Psoriatic Arthritis | Sep 2027S-4321 · Phase 1 |
 Serina TherapeuticsPrivate | 1 asset: 1 Ph 1 | SER-252 (PEOZ-apomorphine)Phase 1 · Parkinson's Disease | 31 Jan 2027SER-252 (PEOZ-apomorphine) · Phase 1 |
 SerodusSER · Oslo Bors | 1 asset: 1 Ph 2 | SER-100Phase 2 · HypertensionPartial signal | None on record |
 Shaanxi Micot Pharmaceutical Technology2335 · HKEX | 1 asset: 1 Ph 3 | MT1013Phase 3 · Chronic Kidney DiseasePartial signal | 26 Nov 2026MT1013 · Phase 3 |
 Shandong Boan Biotechnology Co., Ltd6955 · HKEX | 1 asset: 1 Ph 1 | BA1302Phase 1 · Non-Small Cell Lung Cancer | None on record |
| 1 asset: 1 Ph 3 | F182112Phase 3 · Multiple Myeloma | 31 Dec 2027F182112 · Phase 1 | |
| 1 asset: 1 Ph 2 | ALK202Phase 2 · Non-Small Cell Lung Cancer | Dec 2027ALK202 · Phase 1 | |
| 1 asset: 1 Ph 2 | BW-00112Phase 2 · Atherosclerotic Cardiovascular Disease | None on record | |
| 1 asset: 1 Ph 3 | TTYP01Phase 3 · Alzheimer's Disease | 23 Oct 2028TTYP01 · Phase 2 | |
 Shanghai Bao Pharmaceuticals Co., Ltd.2659 · HKEX | 1 asset: 1 Ph 1 | KJ015Phase 1 · Non-Small Cell Lung Cancer | 31 Dec 2026KJ015 · Phase 1 |
| 1 asset: 1 Ph 1 | CG-0255Phase 1 · Atherosclerotic Cardiovascular Disease | None on record | |
| 1 asset: 1 Ph 2 | EMB-01Phase 2 · Non-Small Cell Lung CancerWeak signal | 30 Dec 2027EMB-01 · Phase 2 | |
| 1 asset: 1 Ph 3 | Sodium oligomannatePhase 3 · Alzheimer's DiseaseReliable signal | None on record | |
 Shanghai HEP PharmaceuticalPrivate | 1 asset: 1 Ph 3 | hepalatidePhase 3 · Type 2 Diabetes | Jun 2027hepalatide · Phase 3 |
| 1 asset: 1 Ph 3 | HL-1186Phase 2/3 · Diabetic Peripheral Neuropathic Pain | None on record | |
| 1 asset: 1 Ph 3 | GC101Phase 3 · Non-Small Cell Lung Cancer | 20 Dec 2026GC101 · Phase 1 | |
| 1 asset: 1 Ph 1 | MWX205Phase 1 · Atherosclerotic Cardiovascular Disease | 26 Oct 2026MWX205 · Phase 1 | |
| 1 asset: 1 Ph 2 | U32 CAR-TPhase 1/2 · Acute Myeloid Leukemia | 31 Dec 2027U32 CAR-T · Phase 1/2 | |
 Shaperon378800 · KOSDAQ | 1 asset: 1 Ph 2 | HY209gelPhase 2 · Atopic DermatitisPartial signal | None on record |
 Shattuck Labs, Inc.STTK · Nasdaq | 1 asset: 1 Ph 1 | SL-172154Phase 1 · Higher-Risk Myelodysplastic Syndromes | None on record |
| 1 asset: 1 Ph 2 | FWD1802Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 1 May 2028FWD1802 · Phase 1/2 | |
| 1 asset: 1 Ph 1 | JY232Phase 1 · Multiple Myeloma | 31 Dec 2028JY232 · Phase 1 | |
| 1 asset: 1 Ph 1 | MS-553Phase 1 · Type 2 Diabetes | 30 Oct 2026MS-553 · Phase 1 | |
| 1 asset: 1 Ph 2 | BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2 · Multiple MyelomaWeak signal | None on record | |
| 1 asset: 1 Ph 2 | RD01 (PEG-EPO)Phase 2 · Chronic Kidney DiseasePartial signal | None on record | |
| 1 asset: 1 Ph 3 | XY0206Phase 3 · Acute Myeloid Leukemia | 1 Jul 2027XY0206 · Phase 3 | |
 Sichuan Huiyu Pharmaceutical Co., Ltd688553 · SSE STAR Market | 1 asset: 1 Ph 2 | HYP-6589Phase 1/2 · Non-Small Cell Lung Cancer | 10 Apr 2028HYP-6589 · Phase 1/2 |
 Sichuan Kelun Pharmaceutical Co., Ltd.002422 · SZSE | 1 asset: 1 Ph 1 | Brexpiprazole long-acting injection (Kelun)Phase 1 · Schizophrenia | None on record |
| 1 asset: 1 Ph 1 | BC008-1APhase 1 · Non-Small Cell Lung Cancer | None on record | |
| 1 asset: 1 Ph 2 | Arketamine (PRT042)Phase 2 · Major Depressive Disorder | None on record | |
 Sihuan Pharmaceutical Holdings0460 · HKEX | 1 asset: 1 Ph 3 | janagliflozinPhase 3 · Type 2 DiabetesReliable signal | None on record |
 Silence TherapeuticsSLN · Nasdaq | 1 asset: 1 Ph 2 | ZerlasiranPhase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 SillaJen, Inc.Private | 1 asset: 1 Ph 1 | BAL0891Phase 1 · Acute Myeloid Leukemia | 24 Dec 2026BAL0891 · Phase 1 |
 Simcha IL-18, Inc.Private | 1 asset: 1 Ph 2 | ST-067Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 SinoMab BioScience3681 · HKEX | 1 asset: 1 Ph 2 | SM17Phase 2 · Atopic DermatitisPartial signal | 25 Apr 2027SM17 · Phase 2 |
 Sinotau Pharmaceutical GroupPrivate | 1 asset: 1 Ph 2 | XTR003Phase 2 · Heart Failure | None on record |
 Siolta TherapeuticsPrivate | 1 asset: 1 Ph 2 | STMC-103HPhase 1/2 · Atopic DermatitisPartial signal | None on record |
 Sirtsei PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | ForvisirvatPhase 2 · Major Depressive DisorderPartial signal | None on record |
 Skye BioscienceSKYE · Nasdaq | 1 asset: 1 Ph 2 | nimacimabPhase 2 · Obesity | 20 Nov 2026nimacimab · Phase 2 |
 SoligenixSNGX · Nasdaq | 1 asset: 1 Ph 3 | Synthetic hypericinPhase 3 · Cutaneous T-Cell Lymphoma | None on record |
 Solu Therapeutics, IncPrivate | 1 asset: 1 Ph 1 | STX-0712Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026STX-0712 · Phase 1 |
 Sorrento Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | STI-6129Phase 1/2 · Multiple Myeloma | 31 Dec 2026STI-6129 · Phase 1/2 |
 Sorriso PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | SOR102Phase 1 · Ulcerative ColitisPartial signal | None on record |
 Sparrow PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | clofutribenPhase 2 · Type 2 DiabetesWeak signal | 31 Dec 2027clofutriben · Phase 2 |
 SpinogenixPrivate | 1 asset: 1 Ph 2 | SPG302Phase 2 · Alzheimer's Disease | 31 Dec 2027SPG302 · Phase 2/3 |
 Stelexis BioSciencesPrivate | 1 asset: 1 Ph 2 | EganelisibPhase 2 · Acute Myeloid Leukemia | 15 Jul 2027Eganelisib · Phase 1 |
 Structure TherapeuticsGPCR · Nasdaq | 1 asset: 1 Ph 3 | aleniglipronPhase 3 · ObesityPartial signal | Sep 2028aleniglipron · Phase 3 |
 Sulfateq B.V.Private | 1 asset: 1 Ph 2 | SUL-238Phase 2 · Parkinson's Disease | None on record |
 Summit TherapeuticsSMMT · Nasdaq | 1 asset: 1 Ph 3 | IvonescimabPhase 3 · Non-Small Cell Lung CancerWeak signal | Dec 2026Ivonescimab · Phase 3 |
| 1 asset: 1 approved | Approved assets only | None on record | |
Suninflam Inc.Private | 1 asset: 1 Ph 1 | SIF001Phase 1 · Epilepsy | 15 Jan 2027SIF001 · Phase 1 |
 Sunshine Guojian Pharmaceutical688336 · SSE STAR Market | 1 asset: 1 Ph 2 | SSGJ-627Phase 2 · Ulcerative Colitis | 28 Feb 2029SSGJ-627 · Phase 2 |
| 1 asset: 1 Ph 2 | LM103Phase 2 · Non-Small Cell Lung Cancer | 31 Dec 2027LM103 · Phase 2 | |
| 1 asset: 1 Ph 2 | GH21Phase 1/2 · Non-Small Cell Lung CancerWeak signal | 30 Dec 2026GH21 · Phase 2 | |
| 1 asset: 1 Ph 1 | IMV102Phase 1 · Multiple Myeloma | 1 Apr 2028IMV102 · Phase 1 | |
 SynDevRx, Inc.Private | 1 asset: 1 Ph 2 | EvexomostatPhase 2 · HR+/HER2- Metastatic Breast Cancer | Dec 2026Evexomostat · Phase 1/2 |
| 1 asset: 1 Ph 1 | SP-101Phase 1 · Major Depressive Disorder | None on record | |
 SynthekinePrivate | 1 asset: 1 Ph 2 | STK-012Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2029STK-012 · Phase 1/2 |
 T3D TherapeuticsPrivate | 1 asset: 1 Ph 3 | T3D-959Phase 2/3 · Alzheimer's DiseasePartial signal | Apr 2031T3D-959 · Phase 2/3 |
 TILT Biotherapeutics Ltd.Private | 1 asset: 1 Ph 2 | TILT-123Phase 1/2 · Non-Small Cell Lung Cancer | Nov 2026TILT-123 · Phase 1 |
 TORL Biotherapeutics, LLCPrivate | 1 asset: 1 Ph 2 | TORL-1-23Phase 2 · Non-Small Cell Lung Cancer | Oct 2027TORL-1-23 · Phase 2 |
 TRex BioPrivate | 1 asset: 1 Ph 1 | TRB-061Phase 1 · Atopic Dermatitis | 2 Sep 2027TRB-061 · Phase 1 |
 TYK Medicines, Inc.2410 · HKEX | 1 asset: 1 Ph 3 | TY-9591Phase 3 · Non-Small Cell Lung CancerWeak signal | 1 Dec 2027TY-9591 · Phase 2 |
 Taiho OncologyPrivate | 1 asset: 1 approved | Approved assets only | Dec 2026ASTX727 · Phase 1 |
 Taiho PharmaceuticalPrivate | 1 asset: 1 Ph 2 | TAS0953Phase 1/2 · Non-Small Cell Lung Cancer | Mar 2030TAS0953 · Phase 1/2 |
| 1 asset: 1 Ph 1 | MitoCellPhase 1 · Parkinson's Disease | 30 Sep 2027MitoCell · Phase 1 | |
 Tanabe Pharma CorporationPrivate | 1 asset: 1 approved | Approved assets only | 15 Dec 2026Cariprazine (Vraylar) · Phase 3 |
| 1 asset: 1 approved | Approved assets only | None on record | |
 Tasca TherapeuticsPrivate | 1 asset: 1 Ph 2 | CP-383Phase 1/2 · Non-Small Cell Lung Cancer | 15 Aug 2028CP-383 · Phase 1/2 |
| 1 asset: 1 Ph 2 | T101Phase 2 · Chronic Hepatitis B | None on record | |
 TauRx TherapeuticsPrivate | 1 asset: 1 Ph 3 | Hydromethylthionine mesylatePhase 3 · Alzheimer's DiseasePartial signal | None on record |
Technoderma MedicinesPrivate | 1 asset: 1 Ph 2 | TDM-180935Phase 2 · Atopic DermatitisPartial signal | None on record |
 Tectonic TherapeuticTECX · Nasdaq | 1 asset: 1 Ph 2 | Fc-relaxin fusion protein (TX45)Phase 2 · Hypertension | 24 Nov 2026Fc-relaxin fusion protein (TX45) · Phase 2 |
 Teligene USPrivate | 1 asset: 1 Ph 2 | SutetinibPhase 2 · Non-Small Cell Lung Cancer | Dec 2027Sutetinib · Phase 2 |
 Tempest TherapeuticsTPST · Nasdaq | 1 asset: 1 Ph 3 | TPST-1120Phase 3 · Hepatocellular Carcinoma | Dec 2028TPST-1120 · Phase 3 |
 Tenax TherapeuticsTENX · Nasdaq | 1 asset: 1 Ph 3 | LevosimendanPhase 3 · Heart FailurePartial signal | 30 Jun 2028Levosimendan · Phase 3 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).